The fastest-growing and largest of the 20 sized Pharmaceuticals markets in South Africa, 2023 to 2033, with active clinical trials.
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Biosimilars | $240 Mn | $2.4 Bn | 26.1% | 7 |
| 2 | Cell Based Immunotherapy | $108 Mn | $945 Mn | 24.2% | 126 |
| 3 | Cannabidiol (CBD) | $143 Mn | $752 Mn | 18% | 0 |
| 4 | Cannabis | $220 Mn | $871 Mn | 14.7% | 2 |
| 5 | Atopic Dermatitis Drugs | $73 Mn | $257 Mn | 13.4% | 3 |
| 6 | Oncology/Cancer Drugs | $1.2 Bn | $2.9 Bn | 9.6% | 121 |
| 7 | Anti-Aging | $573 Mn | $1.4 Bn | 9.3% | 2 |
| 8 | Diabetes Management | $507 Mn | $1.1 Bn | 8.3% | 9 |
| 9 | Alzheimer Drugs | $33 Mn | $71 Mn | 8% | 0 |
| 10 | Contraceptives Drugs | $164 Mn | $355 Mn | 8% | 1 |
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Oncology/Cancer Drugs | $1.2 Bn | $2.9 Bn | 9.6% | 121 |
| 2 | Anti-Aging | $573 Mn | $1.4 Bn | 9.3% | 2 |
| 3 | Diabetes Management | $507 Mn | $1.1 Bn | 8.3% | 9 |
| 4 | Gastrointestinal Drugs | $351 Mn | $619 Mn | 5.8% | 37 |
| 5 | Asthma & COPD Drugs | $322 Mn | $536 Mn | 5.2% | 22 |
| 6 | Biosimilars | $240 Mn | $2.4 Bn | 26.1% | 7 |
| 7 | Cannabis | $220 Mn | $871 Mn | 14.7% | 2 |
| 8 | HIV Drugs | $195 Mn | $385 Mn | 7% | 102 |
| 9 | Contraceptives Drugs | $164 Mn | $355 Mn | 8% | 1 |
| 10 | Cancer Supportive Care Drugs | $161 Mn | $287 Mn | 5.9% | 22 |
2033 values are projected from the 2023 size and the CAGR. Each market name opens its report. Active trials: recruiting, about to start or running.
Biosimilars grows fastest, at 26.1% a year from 2023 to 2033, ahead of Cell Based Immunotherapy (24.2%).
Oncology/Cancer Drugs is the largest, worth about $1.2 Bn in 2023 and $2.9 Bn by 2033 (projected).
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide.